Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Net margin is calculated as Net Income divided by its Revenue. Labo Euromedis's Net Income for the
six
months ended in Dec. 2025 was €-0.23 Mil. Labo Euromedis's Revenue for the
six
months ended in Dec. 2025 was €20.40 Mil. Therefore, Labo Euromedis's net margin for the quarter that ended in Dec. 2025 was -1.13%.
The historical rank and industry rank for Labo Euromedis's Net Margin % or its related term are showing as below:
XPAR:ALEMG'
s Net Margin % Range Over the Past 10 Years
Min: -16.87 Med: 0.59 Max: 38.51
Current: -0.32
XPAR:ALEMG's Net Margin % is ranked worse than 76.07% of 117
companies
in the Medical Distribution industry
Industry Median: 1.47
vs XPAR:ALEMG: -0.32
Labo Euromedis (XPAR:ALEMG) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Labo Euromedis Net Margin % Related Terms
Labo Euromedis Net Margin % Historical Data
* Premium members only.
The historical data trend for Labo Euromedis's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:ALEMG vs MCK, CAH, COR: Net Margin % Comparison
For the Medical Distribution subindustry, Labo Euromedis's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labo Euromedis Net Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Labo Euromedis's Net Margin % distribution charts can be found below:
* The bar in red indicates where Labo Euromedis's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Labo Euromedis (XPAR:ALEMG) has a Net Margin % of -1.13% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Labo Euromedis and its competitors. According to the industry distribution chart, Labo Euromedis ranks #89 out of 117 companies in the Medical Distribution industry, placing it in the top 76.1%.
Is Labo Euromedis' Net Margin % too high?
Labo Euromedis' current Net Margin % is -1.13%. Based on the distribution chart, Labo Euromedis ranks #89 out of 117 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Labo Euromedis has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Labo Euromedis' Net Margin % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Labo Euromedis ranks #89 out of 117 companies for Net Margin %. This places Labo Euromedis in the lower half of its industry. The industry median Net Margin % is 1.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Distribution company?
The median Net Margin % among Medical Distribution companies is 1.47, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Labo Euromedis and its competitors. For the Medical Distribution industry, the median Net Margin % is 1.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labo Euromedis's current Net Margin % is -1.13%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labo Euromedis stock overvalued right now?
Based on GuruFocus' analysis, Labo Euromedis (XPAR:ALEMG) is currently considered Fairly Valued. The stock's GF Value™ is €4.48, compared to a current price of €4.88 — trading 8.9% above its estimated fair value. The current Net Margin % is -1.13%. Labo Euromedis' overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Labo Euromedis (XPAR:ALEMG), the current Net Margin % is -1.13% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Labo Euromedis (XPAR:ALEMG) Overvalued in 2026?
Based on GuruFocus' analysis, Labo Euromedis stock appears to be overvalued.
The current stock price of €4.88 is trading 8.9% above its estimated GF Value™ of €4.48.
GuruFocus considers Labo Euromedis to be Fairly Valued.
Key valuation signals for XPAR:ALEMG:
Net Margin %: -1.13%
GF Value™: €4.48 vs. price of €4.88 (8.9% above fair value)
No single metric tells the full story. See the XPAR:ALEMG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Labo Euromedis is engaged in medical devices. It is engaged in the design, manufacture, rental and export of medical and surgical equipment and products.
61GF Score
Get the complete analysis for XPAR:ALEMG
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ALEMG has been successfully added to your 
